Clinical Trials Browser

Phase 2 × Melanoma × Sunitinib × Clear all

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01551459 2019-10-29

SUAVE

Phase 2 Completed

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT02400385 2017-02-01

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Phase 2 Withdrawn

Melanoma

NCT00577382 2016-12-08

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Phase 2 Completed

52 enrolled 10 charts

Melanoma

NCT00462982 2015-12-30

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

Phase 2 Completed

8 enrolled 6 charts

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00631618 2014-02-25

Clinical Trial of Sutent to Treat Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT01216657 2013-06-04

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Phase 2 Terminated

Melanoma